Inner Banner DBT-BIRAC Joint Call for Proposals on ‘Precision Biotherapeutics- mRNA Therapeutics’ for Fostering High Performance Biomanufacturing under BioE3 Policy.

The DBT-BIRAC Joint Call for Proposals under the BioE3 Policy invites innovative projects in mRNA-based Precision Biotherapeutics to foster high-performance biomanufacturing in India. This initiative supports the development and scale-up of mRNA technologies for applications such as replacement therapies, vaccines, cell therapies, cancer immunotherapy, gene editing, and personalized medicine. Proposals are invited under two categories: (i) Discovery & Application-oriented Integrated Network Research (TRL 3–5) for early-stage innovation and (ii) Bridging the Gap for Scale-up (TRL 5–8) to advance proven concepts toward clinical translation. Eligible applicants include academia, startups, SMEs, and industry, either independently or in collaboration. Funding will be provided by DBT for academic-only projects and by BIRAC for industry-led or joint proposals, with project durations of up to 2 years, extendable to 5 years based on performance. Proposals must align with regulatory requirements, demonstrate scalability, and contribute to indigenous development of affordable, next-generation biotherapeutics.

Last date: May 15, 2025

More details

DBT-BIRAC Joint Call for Proposals on ‘Precision Biotherapeutics- monoclonal antibodies’ for Fostering High Performance Biomanufacturing under BioE3 Policy.

The Department of Biotechnology (DBT) and BIRAC, under the BioE3 Policy, have announced a joint call for proposals to support the development and manufacturing of monoclonal antibodies (mAbs) as part of India's high-performance biomanufacturing initiative. The goal is to enhance access to affordable, high-quality biotherapeutics, strengthen the country's position as a global hub for biotechnology, and build capacity to respond to ongoing and future healthcare needs. Proposals are invited in two categories: (i) Discovery & Application (Technology Readiness Level 3–5), which includes research on novel mAbs for new therapeutic targets, antibody engineering, infectious diseases, diagnostics, and overcoming resistance mechanisms; and (ii) Bridging the Gap for Scale-up (TRL 5–8), which focuses on scaling up bio-betters, manufacturing raw materials indigenously, and validating technologies for commercial readiness. The call is open to academic and research institutions, startups, companies, and LLPs with required credentials and a minimum of 51% Indian ownership.

Last date: May 16, 2025

More details